Nature Communications (Feb 2021)

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

  • Rebekka Duhen,
  • Carmen Ballesteros-Merino,
  • Alexandra K. Frye,
  • Eric Tran,
  • Venkatesh Rajamanickam,
  • Shu-Ching Chang,
  • Yoshinobu Koguchi,
  • Carlo B. Bifulco,
  • Brady Bernard,
  • Rom S. Leidner,
  • Brendan D. Curti,
  • Bernard A. Fox,
  • Walter J. Urba,
  • R. Bryan Bell,
  • Andrew D. Weinberg

DOI
https://doi.org/10.1038/s41467-021-21383-1
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 14

Abstract

Read online

Different neoadjuvant therapies have been proposed to improve immunotherapy for cancer treatment. Here, the authors perform a phase Ib clinical trial where an agonist OX40 antibody provided prior to surgery is well tolerated and increases proliferation and activation of tumor antigen-specific T cells in head and neck cancer patients.